Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

No-Touch vs Conventional Vein Grafts in Coronary Surgery : Seven-Year Clinical Outcomes of the SWEDEGRAFT Randomized Clinical Trial

Dalén, Magnus ; Modrau, Ivy Susanne ; Jeppsson, Anders ; Dreifaldt, Mats ; Duvernoy, Olov ; Ericsson, Anders ; Friberg, Örjan ; Holmgren, Anders ; El-Akkawi, Ali Imad and Hultkvist, Henrik , et al. (2026) In JAMA Cardiology
Abstract

IMPORTANCE: No-touch saphenous vein harvesting preserves perivascular tissue and may improve graft patency after coronary artery bypass grafting (CABG), but whether it reduces long-term clinical events remains uncertain.

OBJECTIVE: To compare 7-year clinical outcomes after no-touch vs conventional saphenous vein harvesting in patients undergoing CABG.

DESIGN, SETTING, AND PARTICIPANTS: This is a prespecified extended follow-up of the SWEDEGRAFT multicenter, binational, randomized clinical trial, which was conducted at 8 cardiac surgery centers in Sweden and 1 center in Denmark. Patients undergoing primary, nonemergent, isolated CABG were eligible for inclusion. The study was conducted between April 20, 2018, and June 3,... (More)

IMPORTANCE: No-touch saphenous vein harvesting preserves perivascular tissue and may improve graft patency after coronary artery bypass grafting (CABG), but whether it reduces long-term clinical events remains uncertain.

OBJECTIVE: To compare 7-year clinical outcomes after no-touch vs conventional saphenous vein harvesting in patients undergoing CABG.

DESIGN, SETTING, AND PARTICIPANTS: This is a prespecified extended follow-up of the SWEDEGRAFT multicenter, binational, randomized clinical trial, which was conducted at 8 cardiac surgery centers in Sweden and 1 center in Denmark. Patients undergoing primary, nonemergent, isolated CABG were eligible for inclusion. The study was conducted between April 20, 2018, and June 3, 2020, and data were analyzed from February 2026 to April 2026.

INTERVENTION: Patients were randomized 1:1 to no-touch or conventional saphenous vein harvesting.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death from any cause, myocardial infarction, or repeat revascularization. Secondary outcomes were the individual components of the primary composite. Outcomes were ascertained through national population-based registries.

RESULTS: A total of 902 patients undergoing primary, nonemergent, isolated CABG were randomized; 900 were included in the modified intention-to-treat population. Among 900 patients, 454 were assigned to no-touch harvesting and 446 to conventional harvesting. Mean (SD) age was 67.0 (7.6) years, 108 patients (12.0%) were women, and 419 patients (46.6%) underwent nonelective surgery. Median (IQR) follow-up was 6.46 (5.92-6.86) years. The primary outcome occurred in 90 patients in the no-touch group and 91 patients in the conventional group (19.8% vs 20.4%; hazard ratio [HR], 0.98; 95% CI, 0.73-1.31; P = .90). The adjusted 7-year risk difference was -0.8% (95% CI, -6.6% to 4.6%). The secondary outcomes did not differ significantly between groups: death (HR, 0.84; 95% CI, 0.53-1.35), myocardial infarction (HR, 0.74; 95% CI, 0.44-1.24), and repeat revascularization (HR, 1.07; 95% CI, 0.73-1.56). Prespecified subgroup analyses showed no heterogeneity in treatment effect.

CONCLUSIONS AND RELEVANCE: In this 7-year follow-up of the SWEDEGRAFT randomized clinical trial, no-touch saphenous vein harvesting was not shown to significantly reduce the composite of death from any cause, myocardial infarction, or repeat revascularization through 7 years of follow-up. Taken together with the previously reported excess of leg wound complications, these findings do not establish a net clinical benefit of routine no-touch harvesting.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03501303.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
JAMA Cardiology
publisher
American Medical Association
external identifiers
  • pmid:42814420
ISSN
2380-6583
DOI
10.1001/jamacardio.2026.4222
language
English
LU publication?
yes
id
c64884b4-b305-4e6b-aa44-024e2acd1cd2
date added to LUP
2026-10-01 08:44:59
date last changed
2026-10-01 08:46:44
@article{c64884b4-b305-4e6b-aa44-024e2acd1cd2,
  abstract     = {{<p>IMPORTANCE: No-touch saphenous vein harvesting preserves perivascular tissue and may improve graft patency after coronary artery bypass grafting (CABG), but whether it reduces long-term clinical events remains uncertain.</p><p>OBJECTIVE: To compare 7-year clinical outcomes after no-touch vs conventional saphenous vein harvesting in patients undergoing CABG.</p><p>DESIGN, SETTING, AND PARTICIPANTS: This is a prespecified extended follow-up of the SWEDEGRAFT multicenter, binational, randomized clinical trial, which was conducted at 8 cardiac surgery centers in Sweden and 1 center in Denmark. Patients undergoing primary, nonemergent, isolated CABG were eligible for inclusion. The study was conducted between April 20, 2018, and June 3, 2020, and data were analyzed from February 2026 to April 2026.</p><p>INTERVENTION: Patients were randomized 1:1 to no-touch or conventional saphenous vein harvesting.</p><p>MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death from any cause, myocardial infarction, or repeat revascularization. Secondary outcomes were the individual components of the primary composite. Outcomes were ascertained through national population-based registries.</p><p>RESULTS: A total of 902 patients undergoing primary, nonemergent, isolated CABG were randomized; 900 were included in the modified intention-to-treat population. Among 900 patients, 454 were assigned to no-touch harvesting and 446 to conventional harvesting. Mean (SD) age was 67.0 (7.6) years, 108 patients (12.0%) were women, and 419 patients (46.6%) underwent nonelective surgery. Median (IQR) follow-up was 6.46 (5.92-6.86) years. The primary outcome occurred in 90 patients in the no-touch group and 91 patients in the conventional group (19.8% vs 20.4%; hazard ratio [HR], 0.98; 95% CI, 0.73-1.31; P = .90). The adjusted 7-year risk difference was -0.8% (95% CI, -6.6% to 4.6%). The secondary outcomes did not differ significantly between groups: death (HR, 0.84; 95% CI, 0.53-1.35), myocardial infarction (HR, 0.74; 95% CI, 0.44-1.24), and repeat revascularization (HR, 1.07; 95% CI, 0.73-1.56). Prespecified subgroup analyses showed no heterogeneity in treatment effect.</p><p>CONCLUSIONS AND RELEVANCE: In this 7-year follow-up of the SWEDEGRAFT randomized clinical trial, no-touch saphenous vein harvesting was not shown to significantly reduce the composite of death from any cause, myocardial infarction, or repeat revascularization through 7 years of follow-up. Taken together with the previously reported excess of leg wound complications, these findings do not establish a net clinical benefit of routine no-touch harvesting.</p><p>TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03501303.</p>}},
  author       = {{Dalén, Magnus and Modrau, Ivy Susanne and Jeppsson, Anders and Dreifaldt, Mats and Duvernoy, Olov and Ericsson, Anders and Friberg, Örjan and Holmgren, Anders and El-Akkawi, Ali Imad and Hultkvist, Henrik and Jensevik Eriksson, Karin and Lidén, Mats and Nozohoor, Shahab and Ragnarsson, Sigurdur and Ternström, Lisa and Themudo, Raquel and Vikholm, Per and Thelin, Stefan and James, Stefan and Sartipy, Ulrik}},
  issn         = {{2380-6583}},
  language     = {{eng}},
  month        = {{09}},
  publisher    = {{American Medical Association}},
  series       = {{JAMA Cardiology}},
  title        = {{No-Touch vs Conventional Vein Grafts in Coronary Surgery : Seven-Year Clinical Outcomes of the SWEDEGRAFT Randomized Clinical Trial}},
  url          = {{http://dx.doi.org/10.1001/jamacardio.2026.4222}},
  doi          = {{10.1001/jamacardio.2026.4222}},
  year         = {{2026}},
}